ZIOPHARM Oncology Inc. (ZIOP)’s Financial Results Comparing With Vericel Corporation (NASDAQ:VCEL)

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Vericel Corporation (NASDAQ:VCEL) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ZIOPHARM Oncology Inc. 1.74M 225.16 75.56M -0.54 0.00
Vericel Corporation 82.87M 9.13 13.09M -0.35 0.00

In table 1 we can see ZIOPHARM Oncology Inc. and Vericel Corporation’s top-line revenue, earnings per share and valuation.


Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
ZIOPHARM Oncology Inc. -4,342.53% 58.6% -89.9%
Vericel Corporation -15.80% -22.9% -14.8%

Risk & Volatility

A 1.91 beta indicates that ZIOPHARM Oncology Inc. is 91.00% more volatile compared to S&P 500. Competitively, Vericel Corporation is 257.00% more volatile than S&P 500, because of the 3.57 beta.


ZIOPHARM Oncology Inc.’s Current Ratio and Quick Ratio are 0.8 and 0.8 respectively. The Current Ratio and Quick Ratio of its competitor Vericel Corporation are 8 and 7.7 respectively. Vericel Corporation therefore has a better chance of paying off short and long-term obligations compared to ZIOPHARM Oncology Inc.

Analyst Recommendations

ZIOPHARM Oncology Inc. and Vericel Corporation Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ZIOPHARM Oncology Inc. 0 0 1 3.00
Vericel Corporation 0 0 1 3.00

ZIOPHARM Oncology Inc. has a 103.81% upside potential and an average target price of $5. Competitively Vericel Corporation has an average target price of $23, with potential upside of 31.73%. Based on the analysts opinion we can conclude, ZIOPHARM Oncology Inc. is looking more favorable than Vericel Corporation.

Insider and Institutional Ownership

ZIOPHARM Oncology Inc. and Vericel Corporation has shares owned by institutional investors as follows: 41.4% and 79.7%. ZIOPHARM Oncology Inc.’s share owned by insiders are 1.77%. Competitively, insiders own roughly 0.5% of Vericel Corporation’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ZIOPHARM Oncology Inc. -8.06% 24.7% 14.07% -29.52% -29.03% -25.6%
Vericel Corporation -0.23% 2.63% 37.57% 29.45% 257.96% 221.83%

For the past year ZIOPHARM Oncology Inc. has -25.6% weaker performance while Vericel Corporation has 221.83% stronger performance.


Vericel Corporation beats on 8 of the 11 factors ZIOPHARM Oncology Inc.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.